1. Home
  2. ABTC vs CADL Comparison

ABTC vs CADL Comparison

Compare ABTC & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Bitcoin Corp.

ABTC

American Bitcoin Corp.

HOLD

Current Price

$4.30

Market Cap

386.0M

Sector

Technology

ML Signal

HOLD

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$5.44

Market Cap

455.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABTC
CADL
Founded
2024
1999
Country
United States
United States
Employees
59
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
386.0M
455.8M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
ABTC
CADL
Price
$4.30
$5.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
10
Target Price
$15.75
★ $17.67
AVG Volume (30 Days)
943.3K
★ 1.4M
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 66.67
58.62
EPS
★ N/A
N/A
Revenue
★ $185,164,000.00
$125,000.00
Revenue This Year
$46.17
N/A
Revenue Next Year
$18.18
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 801.52
N/A
52 Week Low
$4.27
$4.35
52 Week High
$374.25
$14.00

Technical Indicators

Market Signals
Indicator
ABTC
CADL
Relative Strength Index (RSI) 27.23 27.42
Support Level N/A $4.62
Resistance Level $9.16 $5.51
Average True Range (ATR) 0.54 0.72
MACD -0.14 -0.26
Stochastic Oscillator 0.14 4.52

Price Performance

Historical Comparison
ABTC
CADL

About ABTC American Bitcoin Corp.

American Bitcoin Corp is a Bitcoin accumulation platform that integrates scaled Bitcoin mining operations with disciplined accumulation strategies. Its business is engaged in the operation of application-specific integrated circuit ("ASIC") miners for mining Bitcoin and the strategic accumulation of a Bitcoin reserve.

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Share on Social Networks: